Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Simtuzumab in Idiopathic Pulmonary Fibrosis
NCT01769196Phase 2Terminated
- Sponsor
- Gilead Sciences
- Start
- Jan 2013
- Primary completion
- Feb 2016
- Modality
- Monoclonal Antibodies
- Countries
- 14
01
Overview
Phase 2, randomised, double-blind trial in idiopathic pulmonary fibrosis (IPF) comparing Simtuzumab with Placebo (2 arms). Primary endpoints: Progression Free Survival at 148 weeks and PFS Among Participants With sLOXL2 >= 50th/75th Percentile at 148 weeks. Started Jan 2013; status: terminated.
02
Drugs
simtuzumab
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT01769196.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01769196.